CA2647568A1 - Amylin and amylin agonists for treating psychiatric diseases and disorders - Google Patents

Amylin and amylin agonists for treating psychiatric diseases and disorders Download PDF

Info

Publication number
CA2647568A1
CA2647568A1 CA002647568A CA2647568A CA2647568A1 CA 2647568 A1 CA2647568 A1 CA 2647568A1 CA 002647568 A CA002647568 A CA 002647568A CA 2647568 A CA2647568 A CA 2647568A CA 2647568 A1 CA2647568 A1 CA 2647568A1
Authority
CA
Canada
Prior art keywords
amylin
seq
disorder
hamylin
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002647568A
Other languages
English (en)
French (fr)
Inventor
Kevin D. Laugero
Michael R. Hanley
Christine M. Mack
David G. Parkes
Andrew A. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/012601 external-priority patent/WO2006105527A2/en
Application filed by Individual filed Critical Individual
Publication of CA2647568A1 publication Critical patent/CA2647568A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002647568A 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders Abandoned CA2647568A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2006/012601 WO2006105527A2 (en) 2005-03-31 2006-03-31 Amylin and amylin agonists for treating psychiatric diseases and disorders
USPCT/US2006/012601 2006-03-31
PCT/US2006/038919 WO2007114838A1 (en) 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders

Publications (1)

Publication Number Publication Date
CA2647568A1 true CA2647568A1 (en) 2007-10-11

Family

ID=39876652

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002647568A Abandoned CA2647568A1 (en) 2006-03-31 2006-10-04 Amylin and amylin agonists for treating psychiatric diseases and disorders

Country Status (7)

Country Link
EP (1) EP2010208A1 (cg-RX-API-DMAC7.html)
JP (1) JP2009538824A (cg-RX-API-DMAC7.html)
KR (1) KR20080106950A (cg-RX-API-DMAC7.html)
AU (1) AU2006341375B2 (cg-RX-API-DMAC7.html)
CA (1) CA2647568A1 (cg-RX-API-DMAC7.html)
MX (1) MX2008012666A (cg-RX-API-DMAC7.html)
WO (1) WO2007114838A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100204107A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of urodilatin as a therapeutic agent
WO2009043469A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of pneumadin as a therapeutic agent
JP2011525895A (ja) * 2008-06-25 2011-09-29 ノボ・ノルデイスク・エー/エス アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド
JP2013511287A (ja) 2009-11-23 2013-04-04 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー ポリペプチド・コンジュゲート
BR112013007442A2 (pt) 2010-09-28 2019-09-24 Amylin Pharmaceuticals Llc polipeptídeos construídos tendo duração de ação realçada
MX349054B (es) 2010-09-28 2017-07-07 Aegerion Pharmaceuticals Inc Leptinas altamente solubles.
WO2012162547A2 (en) 2011-05-25 2012-11-29 Amylin Pharmaceuticals, Inc. Long duration dual hormone conjugates
WO2012160212A1 (en) 2011-05-25 2012-11-29 Camurus Ab Peptide controlled-release formulations
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
JP7505713B2 (ja) 2019-02-22 2024-06-25 ロヨラ メリーマウント ユニバーシティ アミロイドペプチドバリアント

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
ES2108122T3 (es) * 1991-05-24 1997-12-16 Amylin Pharmaceuticals Inc Composicion a base de amilina o de un analogo de amilina conteniendo opcionalmente insulina, para el tratamiento de la anorexia y de las patologias asociadas.
EP1750752A2 (en) * 2003-11-20 2007-02-14 Neuronova AB Compounds and methods for increasing neurogenesis
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
KR20080003849A (ko) * 2005-03-31 2008-01-08 아밀린 파마슈티칼스, 인크. 비만 및 섭식 장애의 조절, 예방 및 치료를 위한 조성물 및방법

Also Published As

Publication number Publication date
WO2007114838A1 (en) 2007-10-11
AU2006341375A1 (en) 2007-10-11
MX2008012666A (es) 2008-10-13
EP2010208A1 (en) 2009-01-07
AU2006341375B2 (en) 2013-03-21
JP2009538824A (ja) 2009-11-12
KR20080106950A (ko) 2008-12-09
AU2006341375A2 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
EP1888094B1 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
EP1814590B1 (en) Treatment of obesity and related disorders
US7910548B2 (en) Methods for treating obesity
US20080176804A1 (en) Methods for Affecting Body Composition
JP5721624B2 (ja) 内因性高インスリン血症性低血糖症の治療のためのパシレオチドの使用
Crepaldi et al. Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management
AU2006341375B2 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
EP0964695B1 (en) Methods and compositions for treating pain
US20070275877A1 (en) Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
US20090181890A1 (en) Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
CN101208098A (zh) 用于治疗精神病和精神障碍的胰淀素和胰淀素激动剂
AU2005305036B2 (en) Treatment of obesity and related disorders
HK1096314A (en) Methods and compositions for the treatment of lipodystrophy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141006